The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Open-label, multicenter, single-arm phase II study (DeCOG-Trial) to further evaluate the efficacy and safety of ipilimumab in patients with cutaneous melanoma and rare subgroups.
Lisa Zimmer
Consultant or Advisory Role - Bristol-Myers Squibb; Roche
Honoraria - Bristol-Myers Squibb; Novartis; Roche
Other Remuneration - Bristol-Myers Squibb; Roche
Thomas K. Eigentler
Consultant or Advisory Role - Bristol-Myers Squibb; Philogen
Julia-Marianne Vaubel
Honoraria - Bristol-Myers Squibb
Peter Mohr
Consultant or Advisory Role - Bristol-Myers Squibb; GlaxoSmithKline; LEO Pharma; Merck; Novartis; Roche; Scibase
Honoraria - Bristol-Myers Squibb; GlaxoSmithKline; LEO Pharma; Merck; Novartis; Roche; Scibase
Research Funding - Merck
Zeinab Jradi
No relevant relationships to disclose
Felix Kiecker
No relevant relationships to disclose
Jochen Utikal
Consultant or Advisory Role - Bristol-Myers Squibb; GlaxoSmithKline; Roche
Honoraria - Bristol-Myers Squibb; LEO Pharma; MSD; Roche
Carola Berking
Consultant or Advisory Role - Bristol-Myers Squibb
Honoraria - Bristol-Myers Squibb
Eckhart Kämpgen
No relevant relationships to disclose
Axel Hauschild
Consultant or Advisory Role - Amgen; Bristol-Myers Squibb; Celgene; Eisai; GlaxoSmithKline; MedImmune; MELA Sciences; Merck Serono; MSD; Novartis; OncoSec; Roche
Honoraria - Amgen; Bristol-Myers Squibb; Celgene; Eisai; GlaxoSmithKline; MedImmune; MELA Sciences; Merck Serono; MSD; Novartis; OncoSec; Roche
Research Funding - Amgen; Bristol-Myers Squibb; Celgene; Eisai; GlaxoSmithKline; MedImmune; MELA Sciences; Merck Serono; MSD; Novartis; OncoSec; Roche
Edgar Dippel
No relevant relationships to disclose
Rainer Rompel
No relevant relationships to disclose
Michael Fluck
Consultant or Advisory Role - MSD; Roche
Honoraria - Bristol-Myers Squibb
Rudolf Stadler
No relevant relationships to disclose
Rudolf Herbst
Honoraria - Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb
Patrick Terheyden
No relevant relationships to disclose
Claus Garbe
Consultant or Advisory Role - Bristol-Myers Squibb; GlaxoSmithKline; MSD; Novartis; Roche
Honoraria - Bristol-Myers Squibb; GlaxoSmithKline; MSD; Novartis; Roche
Research Funding - Bristol-Myers Squibb; GlaxoSmithKline; Roche
Carmen Loquai
Consultant or Advisory Role - Bristol-Myers Squibb
Honoraria - Bristol-Myers Squibb
Dirk Schadendorf
Consultant or Advisory Role - Bristol-Myers Squibb
Honoraria - Bristol-Myers Squibb